Clinical Trials Logo

Adenocarcinoma clinical trials

View clinical trials related to Adenocarcinoma.

Filter by:

NCT ID: NCT00307723 Terminated - Pancreatic Cancer Clinical Trials

Study of Bevacizumab in Combination With 5-FU, Oxaliplatin and External Beam Radiation Followed by Gemcitabine and Bevacizumab for Locally Advanced Pancreatic Cancer

Start date: May 2006
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is determine the safety of bevacizumab, oxaliplatin, 5-FU, and gemcitabine in combination with external beam radiation therapy(Phase I portion) as well as to begin to collect information about whether this combination treatment is effective in treating patients with locally advanced pancreatic cancer (Phase II portion).

NCT ID: NCT00285415 Terminated - Clinical trials for Advanced Endometrial Adenocarcinoma, Stage III A, B, C

A Phase II Evaluation of Docetaxel and Carboplatin Followed by Tumor Volume Directed Pelvic Irradiation

Start date: April 2005
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine the effectiveness of the combination of the two drugs, docetaxel (Taxotere®) and carboplatin (Paraplatin®) followed by radiation directed at the tumor in treating your endometrial cancer.

NCT ID: NCT00262821 Terminated - Clinical trials for Cervical Adenocarcinoma

Cisplatin and Radiation Therapy With or Without Tirapazamine in Treating Patients With Cervical Cancer

Start date: February 2006
Phase: Phase 3
Study type: Interventional

This randomized phase III trial is studying cisplatin, radiation therapy, and tirapazamine to see how well they work compared to cisplatin and radiation therapy in treating patients with cervical cancer. Drugs used in chemotherapy, such as cisplatin and tirapazamine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. Internal radiation uses radioactive material placed directly into or near a tumor to kill tumor cells. Cisplatin and tirapazamine may make tumor cells more sensitive to radiation therapy. It is not yet known whether giving cisplatin together with radiation therapy is more effective with or without tirapazamine in treating cervical cancer.

NCT ID: NCT00216008 Terminated - Clinical trials for Adenocarcinomas of the Gastroesophageal Junction

Pharmacogenomic Study of Docetaxel and Cisplatin, Followed by Docetaxel, Cisplatin and Irradiation.

Start date: July 2005
Phase: Phase 2
Study type: Interventional

The purpose of this research study is to find out the effectiveness of the experimental combination of Docetaxel, Cisplatin, and radiation therapy administered prior to the surgical removal of your esophageal cancer.

NCT ID: NCT00209079 Terminated - Clinical trials for Gastric Adenocarcinoma

Phase II Trial of Gleevec and Taxotere as a Combined Regimen for Advanced Gastric Adenocarcinoma

Start date: September 2004
Phase: Phase 2
Study type: Interventional

The purpose of this trial is to test the combination of Gleevec® (also known as imatinib mesylate) and Taxotere (also known as docetaxel) in patients with incurable stomach cancer. This study is being performed to see if the combination of Gleevec and Taxotere is an effective treatment for incurable stomach cancer with minimal side effects.

NCT ID: NCT00207831 Terminated - Rectal Cancer Clinical Trials

Trial Testing Ftorafur (UFT) Associated With Neoadjuvant Radiotherapy Versus Radiotherapy Alone in Rectal Adenocarcinoma

UFT RT Phase 3
Start date: July 2004
Phase: Phase 3
Study type: Interventional

RATIONALE: Drugs used in chemotherapy, such as 5-fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing and also as a radiosensibilisant. Radiation therapy uses high-energy x-rays to kill tumor cells. 5-fluorouracil may make tumor cells more sensitive to radiation therapy. Oral 5-fluorouracil is more convenient for ambulatory patients. Giving UFT (Tegafur and Uracil) with radiation therapy before surgery may shrink the tumor so it can be removed. PURPOSE: This phase III trial is studying how well giving UFT with radiation therapy works in treating patients who are undergoing surgery for operable rectal cancer.

NCT ID: NCT00127036 Terminated - Colon Cancer Clinical Trials

Trial for Microarray Analysis of Colon Cancer Outcome-A (MACCO-A)

Start date: October 2003
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine if the investigators can predict the sensitivity or resistance of colon cancer to the two available first line chemotherapy agents.

NCT ID: NCT00126607 Terminated - Clinical trials for Recurrent Salivary Gland Cancer

Trastuzumab in Treating Patients With Metastatic or Recurrent Salivary Gland Cancer

Start date: July 2005
Phase: Phase 2
Study type: Interventional

This phase II trial is studying how well trastuzumab works in treating patients with metastatic or recurrent salivary gland cancer. Monoclonal antibodies, such as trastuzumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them

NCT ID: NCT00117351 Terminated - Clinical trials for Carcinoma, Non-Small-Cell Lung

VELCADE in Previously Treated Patients With Stage IIIB and IV Bronchioloalveolar Carcinoma (BAC) and Adenocarcinoma With BAC Features

Start date: April 2005
Phase: Phase 2
Study type: Interventional

This study will evaluate the safety and efficacy of VELCADE in patients with previously treated stage IIIB and IV bronchioloalveolar carcinoma and adenocarcinoma with bronchioloalveolar features.

NCT ID: NCT00116389 Terminated - Pancreatic Cancer Clinical Trials

Trial of Talabostat and Gemcitabine in Patients With Stage IV Adenocarcinoma of the Pancreas

Start date: n/a
Phase: Phase 2
Study type: Interventional

The purpose of this study is to assess the 6-month survival rate and safety of talabostat and gemcitabine in patients with stage IV adenocarcinoma of the pancreas.